Trifluridine/tipiracil has been approved for the treatment of metastatic colorectal cancer patients who have previously received fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF targeted therapy and anti-EGFR targeted therapy, if the KRAS wildtype gene is detected [5]. Here, VEGFA is linked to metastatic colorectal cancer.